YAP1 increases organ size and expands undifferentiated progenitor cells.

By F. Camargo, S. Gokhale, Jonathan B. Johnnidis, Dongdong Fu, George W. Bell, R. Jaenisch, T. Brummelkamp. Current Biology, 2007

1,292 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/04a9abbb3457c30bd693a101163d0032290fa8e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. G. Halder
3. Bin Zhao
4. Fa-Xing Yu
5. S. Piccolo
6. Randy L. Johnson
7. Duojia Pan
8. M. Cordenonsi

In Molecular Biology

1. K. Guan
2. Bin Zhao
3. Duojia Pan
4. G. Halder
5. Randy L. Johnson
6. Fa-Xing Yu
7. S. Piccolo
8. Xaralabos Varelas

In Oncology

1. D. Morrison
2. K. Guan
3. Bin Zhao
4. J. Shim
5. Duojia Pan
6. Randy L. Johnson
7. S. Piccolo
8. William C. Hahn

Citations in the corpus

• A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). (2010, background): “The Yes-associated protein (YAP) transcription coactivator is a key regulator of organ size (Camargo et al. 2007; Dong et al. 2007).”
• Hsp90 molecular chaperone inhibitors: Are we there yet? (2012, background): “and LATS-deficient mice are prone to develop ovarian cancers and sarcomas (113, 114).”
• The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain (2012, background): “Although YAP is a known oncogene in several cell types (10, 13, 25, 26, 28, 29), a role for YAP in promoting metastasis has not been described to our knowledge.”
• The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development (2008, background): “The mammalian Hippo pathway also contributes to organ size control [51,52] and dysregulation of numerous Hippo pathway components, including Mer, Sav, Lats and YAP, has been observed in human tumors [48,53].”
• The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. (2008, background): “The Hpo pathway appears to restrict cell growth and control organ size in mammals (Camargo et al., 2007; Dong et al., 2007; Zhao et al., 2007).”
• Mst1 and Mst2 maintain hepatocyte quiescence and suppress the development of hepatocellular carcinoma through inactivation of the Yap1 oncogene (2009, neutral): “Yap1 is amplified in a number of human tumor types and transgenic overexpression of Yap1 in mice leads to liver overgrowth and hepatocellular carcinoma (HCC) as well as expansion of progenitor cells in multiple organs (Camargo et al., 2007; Dong et al., 2007; Overholtzer et al., 2006; Zender et al.,”
• Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. (2011, background): “For example, transgenic expression of YAP in the mouse liver results in a liver three times larger than normal and leads to tumor formation if high YAP expression persists (Camargo et al. 2007; Dong et al. 2007).”
• The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment (2013, neutral): “Examples include stem and progenitor cells of the liver, intestine, pancreas, heart, skin, and CNS 12, 106, 142, 156, 15828, 157, 198 .”
• The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. (2010, background): “In fact, YAP has been well established in organ size control and tumorigenesis (Camargo et al. 2007; Dong et al. 2007).”
• The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. (2008, background): “Moreover, conditional YAP overexpression leads to massive organomegaly (Dong et al., 2007; Camargo et al., 2007) and rapid tumorigenesis (Dong et al., 2007), suggesting that the Hpo pathway is a universal regulator of tissue homeostasis in metazoan animals.”
• KRAS and YAP1 converge to regulate EMT and tumor survival (2014, background): “…an oncogene, YAP1 has been shown to drive development of hepatocellular cancer and to induce colonic adenomas in mouse models (Zender et al., 2006; Camargo et al., 2007), although the gene programs regulated by YAP1 to induce transformation may differ from that engaged by YAP1 to mediate survival…”
• YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration (2018, methodology): “…lines used in the experiments have been previously described: Rosa26mT/mG (Muzumdar et al., 2007), tetO-YAP S127A (kindly provided by F. Camargo (Camargo et al., 2007)), Yap1fl/fl (kindly provided by DJ Pan; (Zhang et al., 2010), Villin-CreERT2 (kindly provided by S. Robine; el Marjou et al.,…”
• The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease (2014, background): “Deletion of Mst1/2 or Sav1 drives crypt hyperplasia, leading to an expansion of undifferentiated intestinal progenitors, suggesting that nuclear YAP promotes progenitor proliferation (Cai et al., 2010; Camargo et al., 2007; Zhou et al., 2011a).”
• The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals (2010, background): “, 2006), transgenic overexpression of YAP (Dong et al., 2007; Camargo et al., 2007), or loss”